Olema Pharmaceuticals inc
OLMAHealthcare|Biotechnology|USA
$11.91
-0.38 (-3.09%)
Tangible Book
$5.50
Earnings Power
$4.80
About
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Stock Price
+145.7%(1Y)
Pipeline Summary
6 total trials4
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
Recruiting: 4Completed: 1Active: 1
Active Trials (5)
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
Phase 1Recruiting
Enrollment: 180 participants
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT05508906Metastatic Breast Cancer
Phase 1Recruiting
Enrollment: 190 participants
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer
Phase 3Recruiting
Enrollment: 1,000 participants
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer
Phase 3Recruiting
Enrollment: 510 participants
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
NCT05266105Breast Cancer
Phase 1Active
Enrollment: 60 participants
BioScore
3.8/10
Cautious
Ownership
Recent Insider Trades
Mitchell ShawnteSELL
2026-03-0440,000 shares @ $23.79
Harmon CyrusSELL
2026-01-2010,000 shares @ $26.88
Kovacs Shane William CharlesSELL
2026-01-15103,822 shares @ $28.7
Myles David C.SELL
2026-01-14110,000 shares @ $28.25
Harmon CyrusSELL
2026-01-143,489 shares @ $29.12
Data last updated: Jul 13, 2026, 12:48 PM